drugset / Trial / NCT05842525
Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
RAS mutations are found in nearly half of colorectal cancer patients. However, except for G12C mutation, no driven gene targeted drug can be used. the commonly first-line used treatment regimen is bevacizumab combined with chemotherapy. Angiogenesis is an important therapeutic target in colorectal carcinoma. Fruquintinib is an oral small molecule inhibitor of VEGFR1/2/3, has approved for the third-line treatment of refractory colorectal cancer.
Timeline
- Start
- 2023-10-01
- Primary completion
- 2024-05-28
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fruquintinib | Small molecule | 4 mg | Oral |
| Subject | Fruquintinib | Small molecule | 5 mg | Oral |
| Background | Irinotecan | Small molecule | 150 mg/m2 | — |
| Background | Vinorelbine | Small molecule | 400 mg/m2 | — |
| Background | fluorouracil | Small molecule | 400 mg/m2 | — |
| Background | fluorouracil | Small molecule | 2400 mg/m2 | — |